United States & AbbVie
9 shared events · Importance 4 · Last updated Jul 29, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
United States: The US is part of North America, which held the largest market share in 2025, supported by strong regulatory frameworks and advanced manufacturing.
AbbVie: AbbVie is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
Regulatory
United States: The U.S. regulatory environment and lack of approved products shape the market for women's testosterone therapy.
AbbVie: AbbVie's AndroGel is among testosterone products used off-label by women, potentially benefiting from increased demand.
Sep 15, 2026 · 6 articles
Business
United States: The venue for the IPO, with elevated Treasury yields and higher interest rates shaping a selective backdrop for new listings.
AbbVie: Agreed to invest up to $100 million in a concurrent private placement for a roughly 4.9% post-IPO stake, deepening an existing collaboration after a $335 million payment in May 2025. The move signals continued big-pharma appetite for external innovation.
Sep 21, 2026 · 6 articles
Business
United States: The United States is the regulatory and market jurisdiction for the IPO, with the SEC and Nasdaq based there.
AbbVie: AbbVie's acquisition of Apogee Therapeutics is part of the M&A activity boosting biotech valuations and investor sentiment.
Jul 06, 2026 · 25 articles
Regulatory
United States: The recall affects U.S. patients and the FDA's regulatory environment; no direct economic impact on the country.
AbbVie: AbbVie now owns the brand Pred Forte, but is not directly affected by the recall of the generic version.
Jul 07, 2026 · 38 articles
Business
United States: The United States is the region where Roche and Nurix Therapeutics, Inc. will equally split profits and losses from the commercialization of bexobrutideg.
AbbVie: AbbVie is mentioned as a developer of an approved BTK inhibitor, Imbruvica, which is a competitor to bexobrutideg.
Jun 07, 2026 · 22 articles
Business
United States: Country where Palsonify is approved and where most patients reside.
AbbVie: Mentioned as part of 2026 M&A activity; acquired Apogee for $10.9B.
Jul 06, 2026 · 34 articles
Business
United States: The United States is the primary market for the therapies and the regulatory environment is influenced by the Trump administration's executive order.
AbbVie: AbbVie is a competitor that previously acquired KC Pharmaceuticals for up to $1.2B in 2024, highlighting industry interest in psychedelic therapies.
Jul 16, 2026 · 25 articles
Regulatory
AbbVie: AbbVie is expected to announce a deal with the Donald Trump administration after the holidays.
Dec 19, 2025 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States and AbbVie interact across events, view sentiment trends, and discover connected entities.
Open Dashboard